These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29608461)

  • 41. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
    Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A
    Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
    Blum SI; Tourkodimitris S; Ruth A
    J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies.
    Trivedi MH; Bandelow B; Demyttenaere K; Papakostas GI; Szamosi J; Earley W; Eriksson H
    Int J Neuropsychopharmacol; 2013 Sep; 16(8):1733-44. PubMed ID: 23673347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Tran P; Skolnick P; Czobor P; Huang NY; Bradshaw M; McKinney A; Fava M
    J Psychiatr Res; 2012 Jan; 46(1):64-71. PubMed ID: 21925682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy.
    Thase ME; Montgomery S; Papakostas GI; Bauer M; Trivedi MH; Svedsäter H; Locklear JC; Gustafsson U; Datto C; Eriksson H
    Int Clin Psychopharmacol; 2013 May; 28(3):113-20. PubMed ID: 23485955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder.
    Pangallo B; Dellva MA; D'Souza DN; Essink B; Russell J; Goldberger C
    J Psychiatr Res; 2011 Jun; 45(6):748-55. PubMed ID: 21511276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM
    JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
    Hobart M; Skuban A; Zhang P; Augustine C; Brewer C; Hefting N; Sanchez R; McQuade RD
    J Clin Psychiatry; 2018 May; 79(4):. PubMed ID: 29873953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.
    Kilts CD; Wade AG; Andersen HF; Schlaepfer TE
    Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.
    Thase ME; Chen D; Edwards J; Ruth A
    Int Clin Psychopharmacol; 2014 Nov; 29(6):351-6. PubMed ID: 24978955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
    Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
    Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.
    Gommoll C; Forero G; Mathews M; Nunez R; Tang X; Durgam S; Sambunaris A
    Int Clin Psychopharmacol; 2015 Nov; 30(6):297-306. PubMed ID: 26291335
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study.
    Ozaki N; Otsubo T; Kato M; Higuchi T; Ono H; Kamijima K;
    Psychiatry Clin Neurosci; 2015 Jan; 69(1):34-42. PubMed ID: 24965202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
    Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
    Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vilazodone: in major depressive disorder.
    Frampton JE
    CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial.
    Durgam S; Gommoll C; Migliore R; Chen C; Chang CT; Aguirre M; Thase ME
    Int Clin Psychopharmacol; 2018 Nov; 33(6):304-311. PubMed ID: 30044247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.